Tislelizumab in PD-L1 positive Gastroesophageal junction adenocarcinoma: NCT07763171 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 3
Clinical phase
Not yet recruiting
Recruitment status
244
Planned enrollment
2029-09-01
Primary-completion proxy
Executive view
NCT07763171 evaluates Tislelizumab in PD-L1 positive Gastroesophageal junction adenocarcinoma. The disclosed sponsor is Gruppo Oncologico del Nord-Ovest, the design is Interventional, and the geographic footprint is Italy, Germany, Spain. The first listed primary endpoint is Progression-free survival, assessed over 36 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07763171 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider PD-L1 positive Gastroesophageal junction adenocarcinoma landscape. Drug & Asset MCP drug_fetch was queried for Tislelizumab, while Company & Deal Intelligence MCP organization_fetch was queried for Gruppo Oncologico del Nord-Ovest.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07763171 | Tislelizumab | Phase 3 / Not yet recruiting | Gruppo Oncologico del Nord-Ovest | Italy, Germany, Spain | Progression-free survival 36 months | 2029-09-01 |
| NCT07770113 | Apatinib Mesylate | Phase 2 / Recruiting | The First Affiliated Hospital of Zhengzhou University | China | Median progression-free survival The time from the first day of medication to disease progression or d… | 2026-11-30 |
| NCT07768514 | Acetaminophen/Ibuprofen | Phase 2 / Active, not recruiting | Seoul National University Bundang Hospital | South Korea | Sum of Pain Intensity Differences Over 72 Hours (SPID72) From immediately after surgery through 72 hours after surgery | 2026-11-08 |
| NCT07763652 | BL-ARC002 | Phase 1 / Not yet recruiting | Sichuan Baili Pharmaceuticals Co.,Ltd | China | Phase Ia: Dose limiting toxicity (DLT) Up to 42 days after the first dose | 2028-12-01 |
| NCT07757191 | tPA/HisproUK(Thrombolytic Science International LLC) | Phase 2 / Not yet recruiting | Taipei Veterans General Hospital | Taiwan Province | Pathological complete response (pCR) rate From enrollment to the end of surgical treatment. | 2028-09-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07763171 is a Phase 3, not yet recruiting study with 244 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Progression-free survival” over “36 months.” No additional primary-endpoint description was returned in the selected field set.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 244 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
The protocol identifies Tislelizumab, Cisplatin, Oxaliplatin as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
2 recent result records were selected as contextual evidence for PD-L1 positive Gastroesophageal junction adenocarcinoma. These records do not establish direct evidence for NCT07763171 unless the registration number matches.
Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy Wit…
Phase 1/2; n=71; Number of Participants experiencing AEs = 27 Participants ; Number of Participants experiencing AEs = 14 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04276493
Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Phase 2; n=19; OS(Median) = 7.6 Months (95% Confidence Interval, NA - NA); OS(Median) = 9.5 Months (95% Confidence Interval, 4.6 - 21.6) Source: https://clinicaltrials.gov/ct2/show/results/NCT04209686
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Tislelizumab is indexed as Monoclonal antibody with PD-1 biology and a global stage of Approved. The asset profile lists BeOne Medicines Ltd. as an originator or developer.
Gruppo Oncologico del Nord-Ovest is indexed in Italy with the website http://gonogroup.org. The organization record is used to resolve sponsor identity. The record lists an unreported number of development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Tislelizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07763171
Protocol source: https://clinicaltrials.gov/study/NCT07763171
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
Tislelizumab in PD-L1 positive Gastroesophageal junction adenocarcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Progression-free survival and 2029-09-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
